LOS ANGELES, Sept. 23, 2026 /PRNewswire/ -- Fashion Trust U.S. is proud to announce the appointment of Dr. Omar Mir to its Board of Directors. Bringing a distinguished global background in business, philosophy, and culture, Dr. Mir joins one of American fashion's most influential platforms dedicated to fostering emerging talent.

In addition to his board appointment, Dr. Mir will serve as the driving force behind the 2027 Sustainability Award. This prestigious honor celebrates a new generation of American designers who are redefining the boundaries of responsible luxury and ethical production.

"Omar brings a rare combination of global perspective, intellectual curiosity, and a genuine commitment to the next generation," said Tania Fares, Founder of Fashion Trust U.S. "We are thrilled to welcome him to our Board and to have his support behind the Sustainability Award. He understands that the future belongs to people willing to challenge the way things have always been done, and that is exactly what these young designers are doing."

The Sustainability Award has quickly become a cornerstone of the Fashion Trust U.S. honors, recognizing visionaries who prove that high-level creativity and desirability can coexist with environmental and social responsibility. Since its introduction, the award has brought together leading voices in fashion and culture with some of American design's most exciting emerging talent: Laura Brown presented the 2024 award to Batsheva Hay of Batsheva; Kate Hudson presented the 2025 honor to Nana Kwame Adusei of Kwame Adusei; and Jodie Turner-Smith presented the 2026 award to Maxwell Osborne and Kristy Chen of AnOnlyChild

"The most exciting ideas often begin with someone willing to imagine what doesn't exist yet," said Dr. Omar Mir. "Fashion has always possessed that power. Sustainability asks us to go further and imagine not only what is beautiful, but what is possible. I am honored to join the Board of Fashion Trust U.S. and to support a generation of designers with the courage to shape the future of the industry."

ABOUT FTUS

Fashion Trust U.S. is a nonprofit 501(c)(3) organization dedicated to recognizing and supporting the next generation of U.S.-based emerging fashion designers. Launched in 2022 with its first Award Gala in 2023, the Fashion Trust U.S. initiative provides financial support and fashion industry mentorships to promising designers across the U.S.

Founded by Tania Fares, her vision began in 2011 with the launch of the British Fashion Council's Fashion Trust in the U.K., which she led for a decade. Tania now serves as co-chair of the British Fashion Council (BFC) Foundation.

Each year, winners receive financial grant funding and a one-year intensive mentorship covering budgeting, brand strategy, marketing, social media optimization, merchandising, and overall business growth. As part of the program, each winner is also flown to London to take part in the British Fashion Council's Fashion Trust initiative, an immersive mentorship experience designed to help scale fashion businesses. There, designers are connected with respected industry voices, who generously share their insights, experience, and strategies for long-term success. It's a strong network and community that embodies the true spirit of Fashion Trust.

U.S.-based designers in the categories of Ready-to-Wear, Jewelry, Accessories, as well as recent fashion school Graduates, are invited to apply during the open application period from June through end of November. Applications are free to submit via our website. Eligible designers are required to be in business between two to seven years.

ABOUT DR. OMAR MIR 

Dr. Omar Mir is a global business leader, academic, and philanthropist whose work intersects technology, culture, and social empowerment.

A recognized expert in the global technology ecosystem, Dr. Mir serves as the Advisor on AI and Advanced Technology to The King's Trust International founded by HM King Charles III and as Chief Digital Advisor to HM Princess Royal Anne's Riding for the Disabled Association (RDA UK). His academic contributions include serving on the Imperial College Business School London Advisory Board and holding an appointment as Honorary Visiting Professor. He also serves as a Strategic Advisor to the Commandant of the Royal Military Academy Sandhurst and is a member of their Honour Guard.

Dr. Mir's philanthropic efforts are centered on expanding opportunity for youth. Beyond his role with The King's Trust International, he has provided personal support to over 50,000 children via educational initiatives and holds board or advisory roles with the American Ballet Theatre, Holocaust Museum LA and WeProtect.

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/fashion-trust-us-appoints-dr-omar-mir-to-board-of-directors-names-him-lead-for-2027-sustainability-award-302887050.html

Roche versucht nach einer Phase von Forschungsrückschlägen und Belastungen durch auslaufende Patente, das Tempo in der Medikamentenentwicklung deutlich zu erhöhen. Am Pharma-Investorentag unterstrich die Pharmasparte des Basler Konzerns den Anspruch, in Forschung und Entwicklung weiter zur Spitzengruppe zu gehören. Zentral sind dabei ein strengeres Management der Pipeline, Effizienzprogramme und der verstärkte Einsatz künstlicher Intelligenz entlang der Wertschöpfungskette.

Pharma-Chefin Teresa Graham verwies auf eine sichtbar verbesserte Bilanz seit dem letzten „Pharma Day“: In zehn zulassungsrelevanten Studien habe Roche die gesetzten Ziele erreicht, sechs Programme seien in die zulassungsrelevende Phase vorgerückt, drei weitere in Phase II. Insgesamt verfügt Roche nach eigenen Angaben über bis zu 20 neue Wirkstoffe, die bis 2030 auf den Markt kommen könnten. Einzelne Kandidaten wie das Brustkrebsmittel Giredestrant traut der Konzern dabei jeweils Spitzenumsätze im zweistelligen Milliardenbereich zu.

Um diese Ambitionen abzusichern, verschärft Roche die internen Selektionskriterien. Ende 2023 führte der Konzern mit „The Bar“ einen neuen Bewertungsrahmen für die Pipeline ein. Nur Wirkstoffkandidaten, die klar definierte Anforderungen erfüllen, werden weiterentwickelt. Medizinchef Levi Garraway bezeichnete „The Bar“ als Leitbild für Forschung und Entwicklung. Die Auswahl potenzieller Projekte sei damit spürbar strenger geworden – mit dem Ziel, Ressourcen konsequent auf die Erfolg versprechendsten Programme zu konzentrieren und die Erfolgsquote in späten Studienphasen zu stabilisieren oder weiter zu erhöhen.

Parallel dazu treibt Roche ein Effizienzprogramm voran, um Mittel aus weniger renditestarken in wachstumsstärkere Projekte umzuschichten. Die Entwicklung neuer Medikamente soll deutlich beschleunigt werden, was insbesondere in umkämpften Indikationen wie Onkologie sowie in wachstumsstarken Bereichen wie Herz-Kreislauf- und Stoffwechselerkrankungen an Bedeutung gewinnt. Damit will Roche erwartete Umsatzeinbussen durch Patentabläufe mehr als kompensieren und sich bis zum Ende des Jahrzehnts ein Portfolio aufbauen, das von mehreren potenziellen Blockbustern getragen wird.